US Bancorp DE reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 12,988 shares of the medical equipment provider’s stock after selling 135 shares during the period. US Bancorp DE’s holdings in Hologic were worth $590,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the company. Cleararc Capital Inc. boosted its stake in shares of Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 77 shares during the period. Compton Capital Management Inc. RI boosted its stake in shares of Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 100 shares during the period. Advantus Capital Management Inc boosted its stake in shares of Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock valued at $1,189,000 after buying an additional 116 shares during the period. Shell Asset Management Co. boosted its stake in shares of Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 182 shares during the period. Finally, Curbstone Financial Management Corp boosted its stake in shares of Hologic by 2.4% in the second quarter. Curbstone Financial Management Corp now owns 8,678 shares of the medical equipment provider’s stock valued at $394,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 94.43% of the company’s stock.
Hologic, Inc. (HOLX) traded down 0.83% during mid-day trading on Tuesday, reaching $38.12. The company’s stock had a trading volume of 1,070,114 shares. The company has a market cap of $10.69 billion, a price-to-earnings ratio of 14.20 and a beta of 0.90. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80. The stock’s 50 day moving average is $43.51 and its 200 day moving average is $42.93.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter last year, the business earned $0.51 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/15/us-bancorp-de-decreases-stake-in-hologic-inc-holx.html.
Several equities research analysts have commented on the stock. Stifel Nicolaus boosted their price target on shares of Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Jefferies Group LLC set a $49.00 price target on shares of Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Bank of America Corporation reiterated a “neutral” rating and issued a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Finally, Barclays PLC reiterated an “overweight” rating and issued a $53.00 price target (up from $50.00) on shares of Hologic in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and an average price target of $48.64.
In other Hologic news, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares in the company, valued at $955,257.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the firm’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,627 shares of company stock worth $2,632,911. Company insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.